2021-11-09-世界卫生组织-WHO_Guideline_Development_Group_for_Therapeutics_for_Ebola_Virus_Disease_6页_1mb

Therapeutics for Ebola Virus Disease Guideline Development Group Biosummary

The guideline development group includes a diverse international team of experts with significant experience in infectious disease management and research, particularly related to Ebola Virus Disease (EVD). Key members and their relevant backgrounds are summarized below, highlighting areas such as clinical practice, research, outbreak response, public health, and specific expertise:

Members:

Ethics & Research Leadership:

• Aasim Ahmad: Expert in research ethics for disasters/epidemics (MSF reviewer), authored Pakistan's HBM guidelines, WHO Ethics review workshop facilitator, and involved in COVID-19 WHO Ethics Group/IAB.
• Cindy Albertson: Humanitarian healthcare leader with EVD/Covid program experience, programmatic skills, passion for capacity building in resource-limited settings and developing culturally appropriate interventions.
• Séverine Caluwaerts: Obstetrician-gynaecologist with EVD field experience (MSF, 2008–present). Expertise in pregnancy/ID, cervical cancer screening, and clinical tropical medicine (ITM & Liverpool).
• A Modet Camara: EVD lead physician & researcher (Guinea). Experienced in EVD clinical care (Donka H, Ebola HC, EVD/Lassa/Marburg management) and therapeutic/vaccine trials.
• Ian Crozier: Clinician-scientist (US NIAID/IRF). Focus on EVD sequelae characterization in West Africa survivors, clinical/research/experience from Democratic Republic of the Congo, Guinea, Sierra Leone (2018–present) and prior West Africa EVD studies.
• Hilde De Clerck: Field EVD/MVD clinician coordinator (MSF, 2018). Involved in major EVD outbreaks (West Africa, Kivu), case management, and led the PALM trial (RCT: ZMapp/MAb114/REGN-EB3).
• Susanna Dunachie: Immunology professor (Oxford). Global research on immune responses (melioidosis, SARS-CoV-2), Joint Chief Investigator on immune response consortia. Public health roles (Hamied Professorship, Travel Health Lead).
• William Fischer: Pulmonary/critical care physician (UNC). EVD/Lassa/Covid clinical care provider and researcher in resource-limited settings (WHO role), focuses on EVD/Lassa long-term complications and therapeutics.
• Robert Fowler: Critical care physician/professor (Toronto/CAN). Involved in previous pandemics/outbreaks (Ebola: West Africa, DRC, Guinea/Sierra Leone), expertise in critical care outcomes, infection critical illness, and is a COVID-19 collaborator.
• Bushra Jamil: Infectious diseases physician (Pakistan). Policy advisor, outbreak investigator, COVID-19 vaccination strategist, involved in national operations (NCOC), clinical program development, research, and CE-accredited EID tele-mentoring.

Clinical Management, Research & Operations:

• Patricia Kabuni: EVD and COVID-19 anaesthesiologist/resuscitation specialist (DRC/ALIMA). Designed biosecure ERs, contributor to WHO EVD protocols (first practitioner protocol).
• Charline Kahambu Ngorombi: EVD/Covid frontline clinician (DRC, North Kivu). Extensive DRC health system experience, involved in EVD/Covid clinical management and community engagement.
• Maurice Kakule: EVD managing physician/DRC survivor champion (Beni, DRC). Representing survivor follow-up needs, involved in outbreak response (DRC, WHO Focal Point).
• Richard Kojan: Emergency medicine physician (specialist in ICU/anaesthesia, LMICs). Designveloper of CUBE portable biosecure unit, contributor to clinical works on EVD/Lassa/Sepsis. ALIMA President.
• Marie-Claire Kolié: EVD field physician (Guinea, DRC, MSF/Belgium/ALIMA). International clinical trial site management experience (PALM trial, Butembo, Kinshasa response).
• Sulaiman Lakoh: Infectious disease physician/public health professional (Sierra Leone). Over 10 years' multidisciplinary work, academic/research experience, currently lecturer and consultant.
• Hans-Jörg Lang: Paediatric intensivist/researcher (Germany/UK training). Development NPO/Humanitarian work. EVD outbreak responder (DRC/Guinea). Recent WHO activities (Ebola training, oxygen scale-up).
• J Soka Moses: EVD clinician/researcher (Liberia). Involved in EVD surveillance (2014–16) & survivor care programs, leads clinical trial site operations (Liberia Ministry/NIH) and conducts EVD/health systems research.
• Isekusu Mpinda Fiston: Tropical medicine MD (DRC, University of Kinshasa). Involvement in clinical trials (PALM), EVD therapeutic management/dissemination experience.
• Philippe Mukumbayi Mulumba: EVD clinical management team lead (DRC, Institut National de Recherche Biomédicale). Expertise in clinical response/EVD treatment protocols/training (DRC, Guinea). Research into optimizing treatments published.
• Srinivas Murthy: Infectious disease paediatrician/epidemiologist (Canada/USA). Advisor (WHO/Public Health agencies globally since 2014). Research focus on optimizing EVD/Covid-19 management protocols and outcomes.
• Sorie Samura: National referral coordinator (Medical Lab Science, Sierra Leone). Direct EVD involvement (Connaught hospital, survivor care). Support coordination for healthcare access, holds experience as both HCW and EVD patient.

Key Group Characteristics

• International Representation: Members from Africa, Europe, North America, Asia-Pacific, and the Middle East.
• Broad Expertise: Covers clinical medicine, research, clinical trial coordination, public health policy, ethics, capacity building, emergency preparedness, and survivor support.
• Experience with EVD and Related Diseases: Many members have direct experience working on past EVD outbreaks or ongoing ones (e.g., current DRC, Guinea) and some expertise in related viruses like Lassa or ongoing management (Covid-19) increases applicability.
• Technical & Practical Focus: Includes professionals focused on clinical care protocols, therapeutic administration, biosecurity, diagnostic capacity, and innovative medical unit design (CUBE).
• Learning from Outcomes: Clinical and research interest particularly stems from understanding survivors' long-term issues and improving management protocols globally.